Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

Scott A. Thomson; Angel B. Jaramillo; Maryanne Shoobridge; Kerrie J. Dunstan; Beth Everett; Charani Ranasinghe; Stephen J. Kent; Ke Gao; Jill Medveckzy; Rosemary A. Ffrench; Ian A. Ramshaw

doi:10.1016/j.vaccine.2005.04.045

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

Scott A. Thomson^*, Angel B. Jaramillo, Maryanne Shoobridge, Kerrie J. Dunstan, Beth Everett, Charani Ranasinghe, Stephen J. Kent, Ke Gao, Jill Medveckzy, Rosemary A. Ffrench, Ian A. Ramshaw

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode more antigens safely and is very flexible compared to traditional isolate-based strategies. The SAVINE vaccine strategy is clearly immunogenic, being able to restimulate a range of human HIV-1 specific responses in vitro and induce HIV-1 specific immunity in vivo in mice. Interestingly, different in vivo delivery strategies affected the resulting immunity and immunodominance pattern in mice. This platform strategy could be used for other infections and cancers where T cell responses are important for protection.

Original language	English
Pages (from-to)	4647-4657
Number of pages	11
Journal	Vaccine
Volume	23
Issue number	38
DOIs	https://doi.org/10.1016/j.vaccine.2005.04.045
Publication status	Published - 7 Sept 2005

Access to Document

10.1016/j.vaccine.2005.04.045

Cite this

@article{0fd8c27714c24c5fb0230cc321a66586,

title = "Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use",

abstract = "Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode more antigens safely and is very flexible compared to traditional isolate-based strategies. The SAVINE vaccine strategy is clearly immunogenic, being able to restimulate a range of human HIV-1 specific responses in vitro and induce HIV-1 specific immunity in vivo in mice. Interestingly, different in vivo delivery strategies affected the resulting immunity and immunodominance pattern in mice. This platform strategy could be used for other infections and cancers where T cell responses are important for protection.",

keywords = "Synthetic HIV vaccine",

author = "Thomson, {Scott A.} and Jaramillo, {Angel B.} and Maryanne Shoobridge and Dunstan, {Kerrie J.} and Beth Everett and Charani Ranasinghe and Kent, {Stephen J.} and Ke Gao and Jill Medveckzy and Ffrench, {Rosemary A.} and Ramshaw, {Ian A.}",

year = "2005",

month = sep,

day = "7",

doi = "10.1016/j.vaccine.2005.04.045",

language = "English",

volume = "23",

pages = "4647--4657",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier B.V.",

number = "38",

}

TY - JOUR

T1 - Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

AU - Thomson, Scott A.

AU - Jaramillo, Angel B.

AU - Shoobridge, Maryanne

AU - Dunstan, Kerrie J.

AU - Everett, Beth

AU - Ranasinghe, Charani

AU - Kent, Stephen J.

AU - Gao, Ke

AU - Medveckzy, Jill

AU - Ffrench, Rosemary A.

AU - Ramshaw, Ian A.

PY - 2005/9/7

Y1 - 2005/9/7

N2 - Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode more antigens safely and is very flexible compared to traditional isolate-based strategies. The SAVINE vaccine strategy is clearly immunogenic, being able to restimulate a range of human HIV-1 specific responses in vitro and induce HIV-1 specific immunity in vivo in mice. Interestingly, different in vivo delivery strategies affected the resulting immunity and immunodominance pattern in mice. This platform strategy could be used for other infections and cancers where T cell responses are important for protection.

AB - Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode more antigens safely and is very flexible compared to traditional isolate-based strategies. The SAVINE vaccine strategy is clearly immunogenic, being able to restimulate a range of human HIV-1 specific responses in vitro and induce HIV-1 specific immunity in vivo in mice. Interestingly, different in vivo delivery strategies affected the resulting immunity and immunodominance pattern in mice. This platform strategy could be used for other infections and cancers where T cell responses are important for protection.

KW - Synthetic HIV vaccine

UR - http://www.scopus.com/inward/record.url?scp=23644454804&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.04.045

DO - 10.1016/j.vaccine.2005.04.045

M3 - Article

SN - 0264-410X

VL - 23

SP - 4647

EP - 4657

JO - Vaccine

JF - Vaccine

IS - 38

ER -

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

Abstract

Access to Document

Other files and links

Fingerprint

Cite this